Oramed Pharmaceuticals

ORMP

時価総額 $1.69億

Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and Scilex have yielded strong returns, including a near tripling of its $38.2M Alpha Tau Medical stake and robust loan recovery from Scilex. Alpha Tau Medical's Alpha DaRT product, with approvals in Japan and Israel and a lucrative U.S. licensing deal, offers substantial upside but faces clinical and regulatory risks.

Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).

NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.

Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world's first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platforms In addition, strategic investment by Oramed designed to bring Lifeward towards profitability Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quarters NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor.

Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.

Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group.

Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million , compared to a net loss of $6.1 million in the same period last year Completed full repayment from Scilex: Received approximately $27 million during the period, bringing total repayment to $100 million and representing full return of principal from the Company's strategic investment Strong per-share performance: Basic earnings per share of $1.30; diluted earnings per share of $1.26 Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million The significant improvement in net income was primarily driven by the combination of realized cash returns from Scilex Holding Company and substantial unrealized fair-value gains from the Company's equity holdings in Alpha Tau Medical Ltd.